Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine + dolutegravir switch study in suppressed HIV-1 infection
2023-509751-14-03Phase 2Authorised
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of doravirine and dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Virologic suppression at week 48. Planned start Feb 2025; status: authorised.
02
Drugs
doravirinedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-509751-14-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509751-14-03.